BACKGROUND: HER2 has a predictive value in gastric cancer. However, its association with prognosis remains uncertain. The aim of our study was to estimate the HER2-positive rate in Chinese gastric cancers, compare the classical fluorescence in situ hybridization (FISH) method with the novel bright-field dual color silver-enhanced in situ hybridization (DSISH) detection system, and evaluate the relationship between the HER2 status and prognosis. PATIENTS AND METHODS: Seven hundred and twenty-six resected gastric cancers separately from four clinical centers in China were examined for HER2 by immunohistochemistry (IHC), FISH, and DSISH. RESULTS: The HER2-positive rate was 13%. The consistency between FISH and DSISH results was high (99%; κ = 0.958; P < 0.001). Tumor heterogeneity and polysomy were the main reasons for inconsistency. There was no significant difference in the 3-year overall survival (OS) between HER2-positive and -negative patients (P = 0.959). Multivariate analysis showed that HER2 was not an independent prognostic factor. CONCLUSION(S): HER2 overexpression and amplification occur in a significant number of Chinese gastric cancer patients. Given the obvious advantages and high consistency with FISH, DSISH was superior for evaluating HER2 amplification in gastric cancer. HER2 was not a prognostic factor for gastric cancer in our study.
BACKGROUND:HER2 has a predictive value in gastric cancer. However, its association with prognosis remains uncertain. The aim of our study was to estimate the HER2-positive rate in Chinese gastric cancers, compare the classical fluorescence in situ hybridization (FISH) method with the novel bright-field dual color silver-enhanced in situ hybridization (DSISH) detection system, and evaluate the relationship between the HER2 status and prognosis. PATIENTS AND METHODS: Seven hundred and twenty-six resected gastric cancers separately from four clinical centers in China were examined for HER2 by immunohistochemistry (IHC), FISH, and DSISH. RESULTS: The HER2-positive rate was 13%. The consistency between FISH and DSISH results was high (99%; κ = 0.958; P < 0.001). Tumor heterogeneity and polysomy were the main reasons for inconsistency. There was no significant difference in the 3-year overall survival (OS) between HER2-positive and -negative patients (P = 0.959). Multivariate analysis showed that HER2 was not an independent prognostic factor. CONCLUSION(S): HER2 overexpression and amplification occur in a significant number of Chinese gastric cancerpatients. Given the obvious advantages and high consistency with FISH, DSISH was superior for evaluating HER2 amplification in gastric cancer. HER2 was not a prognostic factor for gastric cancer in our study.
Authors: Yashwanth Subbannayya; Nazia Syed; Mustafa A Barbhuiya; Remya Raja; Arivusudar Marimuthu; Nandini Sahasrabuddhe; Sneha M Pinto; Srikanth Srinivas Manda; Santosh Renuse; H C Manju; Mohammed Abdul Lateef Zameer; Jyoti Sharma; Mariana Brait; Kotteazeth Srikumar; Juan Carlos Roa; M Vijaya Kumar; K V Veerendra Kumar; T S Keshava Prasad; Girija Ramaswamy; Rekha Vijay Kumar; Akhilesh Pandey; Harsha Gowda; Aditi Chatterjee Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742